ASCO puts spotlight on advancing antibody-drug conjugate pipeline

Study abstracts released Thursday give investors and analysts a better look at cancer treatments recently licensed by Merck and BioNTech as well as fresh details on other closely watched ADC candidates.

Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.